Hui Liu1, Jing Huang, Benquan Wu, Yuqi Zhou, Jiaxin Zhu, Tiantuo Zhang. 1. Department of Internal Medicine, Division of Pulmonary and Critical Care, The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Street, Guangzhou, 510630, China.
Abstract
AIMS AND BACKGROUND: Matrix metalloproteinase (MMP) family member MMP-7 (matrilysin) cleaves various cell-surface proteins to alter their effector functions in addition to a broad substrate specificity against extracellular matrix components. Matrilysin expression is closely associated with the advanced clinicopathological stages and unfavorable prognosis. The current study tried to describe the comprehensive impacts of matrilysin on proliferation, and focused on its influence on the susceptibility to FasL-induced apoptosis in A549 lung adenocarcinoma cell line. We also detected the expressions of apoptosis-relative genes to further clarify the underlying mechanisms. STUDY DESIGN: The viability of A549 cells was determined by MTT and the apoptosis was assessed by Hoechst 33342 staining and Annexin V-FITC/PI apoptosis kit. The expressions of apoptosis-relative genes were evaluated by flow cytometry, ELISA, and real-time quantitative RT-PCR, respectively. RESULTS: Overall, matrilysin exhibited the inhibition of cell growth in a dose- and time-dependent manner by arresting in G0/G1 phase of the cell cycle and inducing apoptosis on A549 cells. Although it directly promoted apoptosis at high concentrations, a certain range of matrilysin might protect tumor cells from FasL-mediated death. The underlying mechanism may be due to the imbalance in the susceptibility of surface membrane-bound Fas receptor and ligand to proteolysis activity of matrilysin. CONCLUSION: Our data indicated matrilysin may be multiple, multifarious, and multifaceted functions contributing to early tumor growth. A therapeutic key might be to modulate activity and function of matrilysin under diverse pathological conditions, but not completely eliminate the expression or function.
AIMS AND BACKGROUND: Matrix metalloproteinase (MMP) family member MMP-7 (matrilysin) cleaves various cell-surface proteins to alter their effector functions in addition to a broad substrate specificity against extracellular matrix components. Matrilysin expression is closely associated with the advanced clinicopathological stages and unfavorable prognosis. The current study tried to describe the comprehensive impacts of matrilysin on proliferation, and focused on its influence on the susceptibility to FasL-induced apoptosis in A549 lung adenocarcinoma cell line. We also detected the expressions of apoptosis-relative genes to further clarify the underlying mechanisms. STUDY DESIGN: The viability of A549 cells was determined by MTT and the apoptosis was assessed by Hoechst 33342 staining and Annexin V-FITC/PI apoptosis kit. The expressions of apoptosis-relative genes were evaluated by flow cytometry, ELISA, and real-time quantitative RT-PCR, respectively. RESULTS: Overall, matrilysin exhibited the inhibition of cell growth in a dose- and time-dependent manner by arresting in G0/G1 phase of the cell cycle and inducing apoptosis on A549 cells. Although it directly promoted apoptosis at high concentrations, a certain range of matrilysin might protect tumor cells from FasL-mediated death. The underlying mechanism may be due to the imbalance in the susceptibility of surface membrane-bound Fas receptor and ligand to proteolysis activity of matrilysin. CONCLUSION: Our data indicated matrilysin may be multiple, multifarious, and multifaceted functions contributing to early tumor growth. A therapeutic key might be to modulate activity and function of matrilysin under diverse pathological conditions, but not completely eliminate the expression or function.
Authors: C L Wilson; A J Ouellette; D P Satchell; T Ayabe; Y S López-Boado; J L Stratman; S J Hultgren; L M Matrisian; W C Parks Journal: Science Date: 1999-10-01 Impact factor: 47.728
Authors: Susanne Strand; Petra Vollmer; Lothar van den Abeelen; Daniela Gottfried; Vijay Alla; Hans Heid; Jürgen Kuball; Matthias Theobald; Peter R Galle; Dennis Strand Journal: Oncogene Date: 2004-04-29 Impact factor: 9.867
Authors: J Safranek; L Holubec; O Topolcan; M Pesta; J Klecka; J Vodicka; J Finek; S Kormunda; M Pesek Journal: Anticancer Res Date: 2007 Jul-Aug Impact factor: 2.480
Authors: Morio Nakamura; Gustavo Matute-Bello; W Conrad Liles; Shinichi Hayashi; Osamu Kajikawa; Shu-Min Lin; Charles W Frevert; Thomas R Martin Journal: Am J Pathol Date: 2004-06 Impact factor: 4.307
Authors: Maria Emilia Isolani; Josep F Abril; Emili Saló; Paolo Deri; Anna Maria Bianucci; Renata Batistoni Journal: PLoS One Date: 2013-02-06 Impact factor: 3.240